The Inappropriate Prescription of Oral Proton Pump Inhibitors in the Hospital Setting: A Prospective Cross-Sectional Study

Digestive Diseases and Sciences

Volumn 60, Issue 8, 2015, Pages 2280-2286

  Kelly, Orlaith B ^a   Dillane, Catherine ^a   Patchett, Stephen E ^a   Harewood, Gavin C ^a   Murray, Frank E ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Inappropriate prescribing; Inpatients; Physician; Prescribing patterns; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG USE; DYSPEPSIA; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HOSPITAL; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INAPPROPRIATE PRESCRIBING; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RISK FACTOR; SURGICAL PATIENT; TREATMENT DURATION; AGED; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; AGED; CROSS-SECTIONAL STUDIES; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS;

EID: 84937515835     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3642-8     Document Type: Article

References (20)

1. Wallander MA, Johansson S, Ruigómez A, Rodríguez LAG, Jones R. Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Oxford J Med Family Pract. 2007;24:403–411.
2. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–1960.
3. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103:2308–2313.
4. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol. 2010;56:532–539.
5. IMS Health Report. Leading therapy classes by global pharmaceutical sales. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6025_80528184_80530441,00.html; 2006.
6. National Health Service. PACT centre pages. Drugs for dyspepsia. www.ppa.nhs.uk//news/pact-082004.htm; 2006.
7. van Vliet EP, Otten HJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20:608–612.
8. Choudhry MN, Soran H, et al. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445–448.
9. National Institute for Clinical Excellence. Dyspepsia: managing dyspepsia in adults in primary care. London: NICE; 2004.
10. BNF no. 66, September 2013–March 2014 ISBN-13: 978-0857110855.
11. McGowan B, Bennett K, Tilson L, Barry M. Cost effective prescribing of proton pump inhibitors (PPI’s) in the GMS Scheme. Ir Med J. 2005;98:78–80.
12. Molloy D, Molloy A, O’Loughlin C, Falconer M, Hennessy M. Inappropriate use of proton pump inhibitors. Ir J Med Sci. 2010;179:73–75. doi:10.1007/s11845-009-0426-1.
13. Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16:122–129.
14. Targownik LE, Metge C, et al. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol. 2007;102:942–950.
15. Kaye K, Easton-Carter K, Brien J, Day R. An investigation of hospital prescribing of proton pump inhibitors[Internet]. Sydney: NSW Therapeutic Assessment Group. http://www.ciap.health.nsw.gov.au/nswtag/publications/reports/ppi_project_exec_summary_fv-0701.pdf; 2001.
16. Mat Saad AZ, Collins N, Lobo MM, O’Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31–34.
17. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2.
18. Campbell F, Karnon J, Czoski-Murray C, Jones R. A systematic review of the effectiveness and cost-effectiveness of interventions aimed at preventing medication error (medicines reconciliation) at hospital admission. The University of Sheffield, School of Health and Related Research (ScHARR). J Eval Clin Pract. 2009;15:299–306.
19. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroeoesophageal reflux disease. Am J Gastroenterol. 2000;95:395–407.
20. Wilcox CM, Aillison J, Benzuly K, Borum M, Cryer B, Grosser T. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin AGA Institute. Clin Gastro Hepatol. 2006;4:1082–1089.